Cargando…
Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
One in eight women will be diagnosed with breast cancer in their lifetime and approximately 25% of those cases will be HER2-positive. Current methods for diagnosing HER2-positive breast cancer involve using IHC and FISH from suspected cancer biopsies to quantify HER2 expression. HER2 PET imaging cou...
Autores principales: | Ducharme, Maxwell, Houson, Hailey A., Fernandez, Solana R., Lapi, Suzanne E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689602/ https://www.ncbi.nlm.nih.gov/pubmed/36359554 http://dx.doi.org/10.3390/diagnostics12112710 |
Ejemplares similares
-
Peptide Based Imaging Agents for HER2 Imaging in
Oncology
por: Ducharme, Maxwell, et al.
Publicado: (2020) -
PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68
por: Houson, Hailey A., et al.
Publicado: (2022) -
Biodistribution of (68/67)Ga-Radiolabeled Sphingolipid Nanoemulsions by PET and SPECT Imaging
por: Díez-Villares, Sandra, et al.
Publicado: (2021) -
Site-Specific (68)Ga Radiolabeling of Trastuzumab
Fab via Methionine for ImmunoPET Imaging
por: Yue, Thomas T. C., et al.
Publicado: (2023) -
Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
por: Cai, Huawei, et al.
Publicado: (2023)